Related Experiment Video

Updated: Apr 7, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

1.4K

[Developments in pyoderma gangrenosum therapy in 2015]

P Modiano1

  • 1Service de dermatologie, université catholique de Lille, hôpital Saint-Vincent-de-Paul, boulevard de Belfort, BP 387, 59020 Lille, France.

Annales De Dermatologie Et De Venereologie
|July 15, 2015
PubMed

Insights

Pyoderma gangrenosum diagnosis relies on clinical presentation and revised criteria to exclude other conditions. Emerging auto-inflammatory syndromes offer new treatment avenues beyond corticosteroids and immunosuppressants.

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Context:

  • Pyoderma gangrenosum (PG) diagnosis is primarily clinical, characterized by ulcers with poorly defined, purplish edges.
  • Diagnostic criteria have been updated to improve accuracy and differentiate from other conditions.
  • PG frequently co-occurs with systemic diseases, including endocrine, gastrointestinal, rheumatological, and hematological disorders.

Purpose:

  • To review the current diagnostic landscape of pyoderma gangrenosum.
  • To highlight the association of PG with various systemic diseases.
  • To explore novel therapeutic strategies, including those for auto-inflammatory syndromes.

Summary:

  • The diagnosis of pyoderma gangrenosum (PG) remains largely clinical, focusing on ulcer characteristics.
  • Modified diagnostic criteria aim to enhance specificity by excluding differential diagnoses.
  • A significant percentage of PG patients (75%) present with associated systemic diseases, notably endocrine, gastrointestinal, rheumatological, and hematological conditions.
  • The recognition of auto-inflammatory syndromes like PAPA and PASH syndromes opens new therapeutic avenues.
  • First-line treatments include corticosteroids, with immunosuppressants for steroid-dependent cases.
  • Biotherapies, particularly interleukin-1 inhibitors, show promise as second-line treatments for pyoderma syndrome.

Impact:

  • Improved diagnostic accuracy for pyoderma gangrenosum.
  • Enhanced understanding of the systemic associations of PG.
  • Potential for more targeted and effective treatments through novel therapeutic approaches, including biologics.
Keywords:
Auto-inflammatory diseasesMaladies auto-inflammatoiresPASHPyoderma gangrenosum

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
668
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
587
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
1.2K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
496
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.7K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
663